Older Black Americans are about twice as likely to develop Alzheimer’s or other dementias as older white Americans, according to the Alzheimer’s Association. Yet, awareness and resources to address these diseases within the Black community have often lagged behind. That’s where Alter Dementia steps in.

When Amylyx Pharmaceuticals found out its ALS drug Relyvrio didn't work, the company took the unusual step of voluntarily pulling it off the market.

The Food and Drug Administration is expected to grant full approval to the Alzheimer's drug lecanemab by July 6. But access to the drug may still be limited.